Pharm'Up 
Global pharmaceutical company Lupin Limited has announced that it has received Tentative Approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for a generic version of a key Human Immunodeficiency Virus (HIV) treatment.
Product and Market Impact
- Drug Approved: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg.
- Reference Listed Drug (RLD): This product is the generic equivalent (bioequivalent) of Biktarvy® Tablets, 50 mg/200 mg/25 mg, manufactured by Gilead Sciences, Inc.
- Indication: It is indicated for the treatment of human immunodeficiency virus (HIV) infection in adults and pediatric patients weighing at least 25 kg.
- Market Potential: The Reference Listed Drug, Biktarvy®, had estimated annual sales of a significant USD 16,237 million in the U.S. (IQVIA MAT July 2025), underscoring the value of this future generic opportunity.
The generic tablets will be manufactured at Lupin’s state-of-the-art facility in Nagpur, India.
Tentative approval means that the drug has met the U.S. FDA’s quality, safety, and efficacy standards, but its final marketing approval and launch in the U.S. will be delayed until the patent and/or exclusivity periods for the Reference Listed Drug have expired or the company successfully challenges the patents in court.
This approval marks a strategic milestone for Lupin, positioning the company to enter the highly lucrative U.S. market for HIV antiretroviral therapy once the legal pathways are clear.
About the Author
